Sen. Bernie Sanders and Rep. Elijah Cummings request details after Ariad repeatedly raised the price of its drug. » Read More
The country is now effectively evenly split when it comes to how the Affordable Care Act is viewed.
Niraparib was shown to extend the time elapsed between treatment of ovarian cancer and tumor progression.
Two vaccines for Zika protected against two common strains of the virus in mice, and will enter human trials soon.
Stifel Nicolaus started coverage on Cigna with a buy rating and a $169 target on shares, based on the current Anthem deal value.
The research could lead to the development of new medical sensors that can warn patients about potential symptoms.
The drug, a treatment option for people with Lennox-Gastaut syndrome, has been shown to reduce the number of monthly seizures in some patients.
Legendary has won the rights to "Bad Blood," a film about Theranos, according to The Hollywood Reporter.
Health regulators are proposing to make some Medicare drug payments based on how well those medications work for patients.
A common way of using smartphones fooled two women into thinking they were going blind.
Biotech stocks rallied after a government report said that Medicare cost-cutting measures will not be triggered this year.
Shares of Actuant plummeted more than 7 percent after the company released its fiscal third-quarter earnings.
U.S. House of Representatives Speaker Paul Ryan unveiled a Republican agenda that would repeal Obamacare but keep some of its more popular provisions.
Puberty may be arriving earlier thanks to chemicals, obesity, and other factors, but some say the talk is overblown.
The targets include those who paid the Obamacare penalty or who claimed an exemption to having health coverage.
Opko Health rose more than 5 percent after the U.S. Food and Drug Administration approved the drug Rayaldee.
Big employers will see health costs grow in line with trends, but there's a shift in what's driving spending, PwC's Health Research Institute says.
Get the best of CNBC in your inbox